MOCONNECT recently interviewed GSK’s Christopher Maddox, Director of Site Operations for The Slaoui Center for Vaccines Research in Rockville. The company made news when it selected Rockville to serve as its U.S. R&D Center, furthering strengthening Montgomery County as a major player in global healthcare.
REGENXBIO Inc. (Nasdaq:RGNX) and Dimension Therapeutics, Inc. (Nasdaq:DMTX) today announced that they have entered into a definitive agreement under which REGENXBIO will acquire Dimension in an all-stock transaction for an implied value of approximately $3.41 per share. The boards of directors of both companies have unanimously approved the transaction.
Bruce Booth, D.Phil., a partner at Atlas Venture, astutely observed earlier this year that two key resources fueling the growth of biopharma were until recently somewhat geographically spread among the 10 or so regions of the nation where the industry began to arise a generation ago.
FAIRFAX, Va., Aug. 24, 2017 /PRNewswire/ — The Inova Personalized Health Accelerator (IPHA) announced today that health and biosciences industry veteran Michael Thomas has been appointed Director of the Accelerator. Prior to joining Inova, Michael was founder and CEO of Appian Partners, an Annapolis life sciences consulting practice. His med-tech experience has spanned several early stage, growth stage, and turn-around ventures as CEO of Appian Partners, ReGear Life Sciences, NuSomnea, Tanzen Medical, Mommy’s Medicine Cabinet, Appian Medical, iSonea, and NovaSom. He also served on the board of directors for AdvaMed and Circadiance. He started his career in the pharmaceutical industry with Merck & Company and GlaxoSmithKline. Michael earned a BS in Microbiology from Cornell University.
“Mike’s experience in raising over $125 million in venture capital, angel funding, and private equity combined with his leadership experience as a chief executive in startup and public companies will provide IPHA participants with outstanding guidance as they develop their company to meet the needs of health system markets,” said Todd Stottlemyer, CEO of the Inova Center for Personalized Health (ICPH). Michael will be one of four directors that support the operations and portfolio of IPHA. He joins Hooks Johnston and Pete Jobse, with a fourth director to be named in the future.
IPHA, a variation on the traditional accelerator model, is differentiated by rolling admissions; with a limit of no more than 6 companies at one time and customized programs that provide individual companies the capital investment, mentoring, and networking they need to accelerate the development and commercialization of their products. The program also affords companies direct access to the Inova Health System to validate innovations and demonstrate value.
The Inova Health System previously announced the formation of IPHAwhich will commence operations in the third quarter of 2017. IPHA provides qualified healthcare technology start-ups with a unique series of services to help them grow into sustainable businesses. These services include C-suite coaches, customized plans for commercialization, capital investment, and connections to potential customers. An announcement calling for applicants will be issued at the end of the summer.
About Inova Personalized Health Accelerator
The Inova Personalized Health Accelerator is a unique program that provides C-suite coaches, customized plans, early stage capital, connections to strategic partners and later stage capital, and connections to customers for healthcare technology and services entrepreneurs. This bespoke approach to enhance med-tech entrepreneurs’ efforts to accelerate new companies through the early stages of product design, capital formation and commercialization will serve as the foundation for a stronger healthcare ecosystem in the mid-Atlantic region. Additional program information is located at www.inovapha.org.
About Inova
Inova is a global leader in personalized health, which leverages precision medicine to predict, prevent and treat disease, enabling individuals to live longer, healthier lives. At Inova, we serve more than 2 million people each year from throughout the Washington, DC, metro area and beyond.
We are shaping the future of health through our integrated network of hospitals, primary and specialty care practices, emergency and urgent care centers, outpatient services and destination institutes. Our commitment to health and wellness is further reflected in our sustainable practices. Inova is home to world-class researchers, expert medical specialists and renowned scientists, who are driving innovation to improve patient care, prevent disease and promote wellness. For more information, visit www.inova.org, or find Inova on Facebook, Twitter and LinkedIn.
CONTACT: Kelly Schlageter, rel=”nofollow”>kelly.schlageter@inova.org, 571-472-0200
View original content:http://www.prnewswire.com/news-releases/inova-personalized-health-accelerator-names-michael-thomas-as-director-300508587.html
SOURCE Inova Health System
RICHMOND, Va.–(BUSINESS WIRE)–Virginia Bio, the premier statewide non-profit association of the life science industry in Virginia, elected Andrew J. Krouse to a two-year term as Chairman of the Board of Directors, during the annual meeting of the Board held at i.Lab at UVA.
“My priorities will be to increase access of Virginia companies to private investment, engender a richer active engagement of all of our members in our community, and better communicate the story of Virginia bioscience commercialization to policy makers and other stakeholders.”http://https://pbs.twimg.com/profile_images/2151221424/VABIO_400x400.pnghttp://http://www.vabio.org/resource/resmgr/VABIO_rgb.jpg
Andrew Krouse, MALS, is the President & CEO of Cavion, Inc., a venture-backed pharmaceutical company in Charlottesville, developing best-in-class T-type calcium channel (Cav3) therapies that restore the brain’s natural rhythms and normal function in diseases that share a common pathophysiology, including movement disorders, epilepsy, and pain. Mr. Krouse has over a decade of biotech leadership experience as founder of Tau Therapeutics LLC, Xdynia LLC and Cavion, Inc. Mr. Krouse has served as a member of the Virginia Bio Board of Directors since 2011, most recently as Vice-Chairman.
“I look forward to working with my colleagues throughout industry and academia to keep this great organization going strong,” said Mr. Krouse. “My priorities will be to increase access of Virginia companies to private investment, engender a richer active engagement of all of our members in our community, and better communicate the story of Virginia bioscience commercialization to policy makers and other stakeholders.”
Alan Connor, President & CEO of Cadence Inc., Staunton, was elected as Vice-Chairman. Cadence Inc. is a full-service contract manufacturer and leading supplier of advanced products, technologies and services to medical device, life science, and industrial companies worldwide.
Ross Dunlap, CEO and a co-founder of Ceres Nanosciences, Prince William County, was elected Secretary. Among other things, Mr. Dunlap is directing the clinical development, validation, and market launch of a novel Lyme Antigen Test that will provide the most sensitive and accurate detection of Lyme disease.
The board also elected as a new Director Eric Paradise, who is a Senior Director in business development at MedImmune, the global biologics R&D arm of AstraZeneca.
Other officers and members of the Executive Committee of Virginia Bio Board are Crystal Icenhour, CEO Aperiomics, Ashburn, Immediate Past Chair; Jeff Conroy, CEO Embody LLC, Norfolk, Past Chair; Carrie Roth, CEO VA Bio+Tech Park, Richmond, Treasurer; and Jim Powers, CEO HemoShear, Charlottesville.
The complete list of Virginia Bio board members is at http://www.vabio.org/?leadership.
About Virginia Bio
Virginia Bio is the premier statewide non-profit trade association for life sciences, promoting the considerable scientific and economic impact of the life sciences industry in the Commonwealth of Virginia. Virginia Bio is an advocate for innovation and entrepreneurship, and for the biopharmaceutical, and other health technology industries among federal, state and local policy-makers. Virginia Bio is the official state affiliate of BIO (the Biotechnology Innovation Organization), AdvaMed and MDMA (Medical Device Manufacturers Association), and works closely with PhRMA (Pharmaceutical Research and Manufacturers of America). To learn more, visit www.vabio.org or follow Virginia Bio on Twitter at @VABio
Virginia Bio
Sherri Halloran, 804-643-6360
Vice President Membership and Programs
halloran.sherri@vabio.org
www.vabio.org
Emergent BioSolutions has agreed to acquire GlaxoSmithKline’s (GSK) anthrax monoclonal antibody, raxibacumab, for around $96m.
Raxibacumab is a fully human monoclonal antibody, which secured approval from the US Food and Drug Administration (FDA) for the treatment and prophylaxis of inhalational anthrax due to Bacillus anthracis.
New Enterprise Associates has closed its 16th flagship fund on $3.3 billion, per the Wall Street Journal, the largest venture vehicle ever raised.
ROCKVILLE, Md.–(BUSINESS WIRE)– GlycoMimetics, Inc. (NASDAQ: GLYC) today announced the closing of its underwritten public offering of 8,050,000 shares of its common stock at a public offering price of $11.50 per share, which includes the exercise in full by the underwriters of their option to purchase up to 1,050,000 additional shares of common stock. All of the shares in the offering were offered by GlycoMimetics. The aggregate gross proceeds to GlycoMimetics from the offering, before deducting the underwriting discounts and commissions and offering expenses, were approximately $92.6 million.
FAIRFAX COUNTY, Va.–(BUSINESS WIRE)–Governor Terry McAuliffe today announced that Granules India Ltd., a vertically integrated pharmaceutical company, will invest $35 million into its wholly owned subsidiary, Granules Pharmaceuticals Inc., to expand its pharmaceutical R&D and manufacturing capabilities in Fairfax County. Virginia successfully competed against New Jersey for the project, which will create 102 new jobs. In 2014, the company invested $15 million to establish the wholly-owned subsidiary operation, creating 75 jobs.
“The work that Granules India is doing here in pharmaceutical manufacturing and research is a great example of how the life-science industry is growing rapidly here, and the company joins more than 400 other foreign-owned firms that have chosen Fairfax County for U.S. expansion.”
Tweet this
“The Fairfax County EDA has greatly enjoyed helping Granules India build its presence here. This announcement is important in several ways,” said Gerald L. Gordon, Ph.D., president and CEO of the Fairfax County Economic Development Authority. “The work that Granules India is doing here in pharmaceutical manufacturing and research is a great example of how the life-science industry is growing rapidly here, and the company joins more than 400 other foreign-owned firms that have chosen Fairfax County for U.S. expansion.”
Granules India Ltd. is headquartered in Hyderabad, India. The company manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates and finished dosages, distributed to customers in regulated and semi-regulated markets. Granules India operates in a 100,000-square foot facility in the Chantilly area of Fairfax County. The company is conducting research and development to formulate products, and intends to manufacture products in the location as well.
“Setting up a development and manufacturing presence in the United States was the first step we took as a company to meet our strategic focus on strengthening our global presence,” said Priyanka Chigurupati, executive vice president, Granules India Ltd. “We are very excited about our plans for expansion in Fairfax County. There is a lot of untapped potential with a highly educated and technically savvy workforce, reliable security, diverse amenities and state-of-the-art infrastructure including Dulles International Airport, the Port of Virginia, and the expanded Metrorail in close proximity.”
The Virginia Economic Development Partnership will support Granules’ new job creation through its Virginia Jobs Investment Program. State-funded VJIP provides consultative services and funding to companies creating new jobs or experiencing technological change to support employee training activities.
Time magazine called Fairfax County “one of the great economic success stories of our time.” Business growth and innovation helps Fairfax County fund the nation’s top-rated school system and other public services that contribute to the quality of life of residents. Fairfax County offers businesses a state-of-the-art telecommunications infrastructure, access to global markets through Washington Dulles International Airport, a vibrant investment capital community and a highly skilled, well-educated workforce.
The award-winning Fairfax County Economic Development Authority promotes Fairfax County as a business and technology center. The FCEDA offers site location and business development assistance, and connections with county and state government agencies, to help companies locate and expand in Fairfax County. In addition to its headquarters in Tysons Corner, Fairfax County’s largest business district, the FCEDA maintains marketing offices in six important global business centers: Bangalore, Berlin, London, Los Angeles, Seoul and Tel Aviv. Follow the FCEDA on Facebook, Twitter, LinkedIn.
Contacts
FCEDA
Alan Fogg, +1 703-790-0600 (office)
571-213-5065 (mobile)
afogg@fceda.org
or
Granules India
Priyanka Chigurupati, +1 973-906-1731
pchigurupati@granulesindia.com
The University of Virginia’s Board of Visitors on Friday approved an academic affiliation with the Inova Health System Foundation that includes a research institute and a UVA School of Medicine regional campus.
